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Abstract Patients with acute myocardial infarction (AMI)
and diabetes mellitus, as well as patients admitted with
elevated blood glucose without known diabetes, have
impaired outcome. Therefore intensive glucose-lowering
therapy with insulin (IGL) has been proposed in diabetic or
hyperglycaemic patients and has been shown to improve
survival and reduce incidence of adverse events. The
current manuscript provides an overview of randomised
controlled trials investigating the effect of IGL. Furthermore,
systematic glucose–insulin–potassium infusion (GIK) has
been studied to improve outcome after AMI. In spite of
positive findings in some early studies, GIK did not show any
beneficial effects in recent clinical trials and thus this concept
has been abandoned. While IGL targeted to achieve normo-
glycaemia improves outcome in patients with AMI, achieve-
ment of glucose regulation is difficult and carries the risk of
hypoglycaemia. More research is needed to determine the
optimal glucose target levels in AMI and to investigate
whether computerised glucose protocols and continuous
glucose sensors can improve safety and efficacy of IGL.
Keywords Acute coronary syndrome . Unstable angina
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Introduction
Diabetes is common in patients presenting with an acute
coronary syndrome (ACS). Furthermore, hyperglycaemia or
impaired glucose tolerance is present inmore than a third of ACS
patients without known diabetes [1]. Both in patients with
diabetes and in non-diabetics with evolving myocardial
infarction (AMI) hyperglycaemia is associated with increased
in-hospital death (RR 1.7 [1.2–2.4]), and with other adverse
events including cardiac arrest, cardiogenic shock and pulmo-
nary oedema [2–4]. Also in patients with stable coronary artery
disease, diabetes is associated with a higher 1-year incidence of
death and cardiovascular events (13.0% vs. 5.6%) [5].
Hyperglycaemia has been recognised both as mediator and as
marker of adverse outcomes in ACS patients. Elevated glucose
levels can reflect the severity of disease when it results from
elevated catecholamine and cortisol levels. Also, the presence of
additional conditions such as infection or sepsis may further
disturb carbohydrate metabolism and glucose levels. Insulin
resistance due to pre-existent diabetes (recognised or unrecog-
nised) amplifies the stress-related effects on glucose levels. In
patients with AMI, hyperglycaemia is associated with higher
free fatty acid concentrations [6], insulin resistance and
impaired myocardial glucose metabolism, resulting in an
increased oxygen consumption and consequently a more
severe ischaemic state [7]. Insulin limits the detrimental
effects of hyperglycaemia by reducing glucose levels. Also,
insulin may improve myocardial glucose utilisation by
reducing free fatty acid concentrations due to its inhibitory
effect on lypolysis [7]. Finally, insulin has antithrombotic,
anti-inflammatory and vasodilative properties [8–10].
In critically ill patients insulin therapy improves outcome
[11–13]. Also in hyperglycaemic patients with AMI,
glucose-lowering insulin therapy is associated with reduced
mortality at 7 and 30 days when compared with standard
treatment (11.6% and 15.8% vs. 16.5% and 22.1%,
respectively) [14]. Similarly, in patients with stable coro-
nary disease, treatment of hyperglycaemia is associated
with a reduction in cardiovascular events at 1 year
(HR 0.22 [0.05–0.97]) [15]. The results of these observa-
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tional studies have led to three randomised controlled trials
investigating the effect of intensive glucose-lowering
insulin therapy (IGL) on outcomes in hyperglycaemic
diabetic, and non-diabetic patients admitted with AMI
[11, 16, 17].
A different concept of insulin treatment in ACS was
tested in the form of a glucose–insulin–potassium
infusion (GIK). This treatment was developed as a
‘polarising solution’ to prevent arrhythmias and avoid
further ischaemic damage in unselected patients with
acute myocardial infarction [18, 19]. From 1960 onwards,
different (randomised) trials have been done, utilising GIK
infusion and later insulin therapy in ACS patients.
The purpose of this manuscript is to provide an overview of
the evidence for implementing IGL or GIK in ACS patients by
comparing trials with regard patient characteristics, reperfusion
treatment, study protocols and outcomes.
Methods
A systematic PubMed search was performed to identify
all clinical trials with insulin (both IGL and GIK were
included) in patients with unstable angina or AMI.
MeSH terms used were ‘myocardial infarction’, ‘angina,
unstable’, ‘insulin’ and ‘glucose’. All abstracts were
screened; when fitting the criteria the manuscript was
obtained and reviewed. Other studies were included
through references. Hazard ratios and confidence inter-
vals for short-term mortality were recalculated to
facilitate comparisons.
Results and Discussion
The initial query gave 356 hits. After screening, 20 GIK
and three IGL trials were reviewed. For the GIK studies
performed before 1994, a review article was selected that
provided a thorough analysis of these trials. From 1994
to 2004, six GIK trials were published that included
patients with AMI or unstable angina. These differed
from the prior studies in that the included patients
received reperfusion therapy. The three IGL studies are
discussed separately and in more detail as they are more
relevant to current clinical practice. An overview of the
study characteristics is given in Table 1. Outcomes and
glycaemic parameters are provided in Table 2.
Glucose Normalisation
In the prethrombolytic era, two observational studies using
historical controls showed inconsistent results for the
beneficial effect of insulin treatment in diabetic AMI
patients. Clark et al. reported a reduced incidence of
arrhythmias and death in the patients treated with IGL
[20]. In contrast, Gwilt et al. did not find a difference in
mortality in diabetics treated with an insulin infusion
protocol, though they did find a higher mortality rate in
diabetic vs. non-diabetic AMI patients [21].
Between 1990 and 2004 three randomised controlled trials
were performed including patients with AMI and known
diabetes or hyperglycaemia at admission [11, 16, 17]. Patients
from Europe [11, 16] and Australia [17] were included; study
size varied from 240 to 1253 patients. IGL was administered
via an intravenous insulin regime for at least 24 h to achieve
glucose levels of <10.0 mmol/l. The DIGAMI studies
included a 3 month subcutaneous insulin regimen as well.
Admission glucose levels ranged from 10.8 to 15.7 mmol/l.
At 24 h, glucose levels were reduced in both IGL and control
groups, but more so in the IGL groups. The difference in
glucose levels between patients allocated to IGL or conven-
tional treatment ranged from 2.1 mmol/l (DIGAMI-1) to
0.7 mmol/l (the average over 24 h in HI-5). Long-term
mortality was lower in two of the three studies, but this was
statistically significant in DIGAMI-1 only. However, mortality
was lower in the control group of DIGAMI-2.
DIGAMI-1 [11] was the first randomised trial for IGL,
and showed a 29% relative reduction (18.6% vs. 26.1%) in
1-year mortality among hyperglycaemic or diabetic AMI
patients treated with IGL during the first 12 h and
continued subcutaneously for 3 months. Interestingly, about
half of this difference in mortality was achieved in the first
3 months, while additional benefit occurred at longer
follow-up. In this trial, about half of the patients received
thrombolytic therapy. The target for IGL in DIGAMI was a
glucose level of 7–10 mmol/l.
The second DIGAMI [16] trial was designed to verify
whether normalisation of serum glucose (target 5–
7 mmol/l for fasting glucose) would further improve
outcome. Three treatment regimens were compared: IGL
24 h, IGL 24 h continued for 3 months subcutaneously
and a control group. No significant difference was seen in
survival in the IGL groups compared with conventional
management (P=0.203) while, unexpectedly, the highest
survival rate was observed in the control group.
The discrepancy between the first and second DIGAMI
can be attributed to several factors. Most importantly,
patients were less ill and admission glucose levels were
lower in DIGAMI-2 than in DIGAMI-1 and the investigators
did not succeed in normalising glucose levels in the IGL
groups. The difference in glucose levels vs. controls was
2.1 mmol/l in DIGAMI-1 and only 0.9 mmol/l in DIGAMI-2.
Additionally, in DIGAMI-2, 14% of the patients in the control
group also received insulin infusion during hospital admission,
the overall admission glucose levels were lower and reperfu-
sion treatment was given more often (78% vs. 50%).
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The more recent HI-5 study [17] did find a lower
mortality at 3 and 6 months in favour of IGL, which is
consistent with DIGAMI-1, although this was not statistically
significant. There was also a lower incidence of heart failure
during admission (12.7% vs. 22.8%; P=0.04) and reinfarction
within 3 months (2.4% vs. 6.1%; P=0.05) in the insulin-
treated group. The mortality rates in the HI-5 study were
markedly lower than those in the DIGAMI studies. This can
be explained by the younger population (62 vs. 68 years), by
inclusion of non-diabetic subjects (48%), increased use of
reperfusion therapy (67% vs. 50%) and overall improved care
in the more recent time period (2001–2004 vs. 1990–1993) of
the HI-5 vs. the DIGAMI study.
Glucose Target Range and Hypoglycaemia
The results of DIGAMI-2 illustrate the difficulty in
regulating glucose levels and achieving ‘optimal’ target
ranges. DIGAMI started insulin infusion in patients with a
glucose level of 11 mmol/l or higher, and aimed for values
between 7 and 10 mmol/l. After the landmark trial from
Leuven [13], in an intensive care population, found a
10.4% absolute difference in mortality in favour of IGL
targeted to 4.4–6.1 mmol/l, many subsequent trials used
similar targets. However the later trials were unable to
reproduce the results [22]. The most recent NICE-SUGAR
trial even reported a higher incidence of death, similar to
DIGAMI-2. Since hypoglycaemic episodes occurred more
frequently in the IGL group, this resulted in a modification
in the ACC/AHA guidelines [23] to use 10 mmol/l as a
threshold for initiating treatment in STEMI patients. The
ESC guidelines [24] still mention a target range of 5 to
7.8 mmol/l; however, these were established before the
NICE-SUGAR results appeared.
The fear for hypoglycaemia in certain IGL protocols seems
grounded, and prevention requires frequent measurement or a
wider glucose target range. Meijering et al. [25] evaluated
insulin protocols in 24 studies (including six with AMI
patients). The best results were found using a dynamic scale
protocol for continuous intravenous insulin infusion, com-
bined with frequent blood glucose measurement and taking
into account changes in glucose levels rather than single
values.
Compliance with any insulin protocol is difficult to
achieve. Computerised insulin protocols exist [26–28] and
can improve protocol compliance and glycaemic regulation;
however, frequent measurements are required. More recent-
ly, a closed loop system for glycaemic regulation in the
intensive care unit was developed using a continuous
glucose sensor [29]. This, however, requires further testing.
Also, the reliability of continuous glucose sensors needs
further improvement [30] and validation is necessary in the
AMI patient population, particularly in patients with heart
failure and hypoperfusion of the skin and subcutaneous
tissues.
Glucose–Insulin–Potassium Therapy
A meta-analysis by Fath et al. [31] of GIK trials done in the
pre-reperfusion therapy era (before 1988) showed a lower
mortality in the GIK-treated group than in controls (16%
vs. 21%; P=0.004). However, in later trials that included
patients receiving reperfusion therapy (either by thrombol-
ysis or mechanical), GIK did not show beneficial effects.
Table 1 Overview of randomised controlled trials
Study name Inclusion % PCI/thrombolysis/
CABG/none
Location Period
Fath et al. [31] Meta-analysis of nine RCTs implementing
GIK in AMI
0/1/0/99 Multicentre, international 1965–1987
Pol-GIK Chest pain and ECG changes <24 h,
IDDM excluded
0/60/0/40 Multicentre (16), Poland 1994–1995
Krljanac et al. [32] STEMI patients 0/100/0/0 Belgrade, Serbia 2000–2001
GIPS I AMI presenting within 24 h of symptoms 91/0/4/5 Zwolle, the Netherlands 1998–2001
GIPS II STEMI <24 h, heart failure excluded 93/2/0/5 Multicentre (7), the Netherlands 2003–2004
Create-ECLA STEMI presenting within 12 h of symptom onset 9/74/0/7 Multicentre (470), international (>10) 1998–2004
OASIS 6 STEMI presenting within 24 h (later 12 h) 31/45/0/24 Multicentre (447) international (41) 2003–2004
DIGAMI I AMI <24 h and diabetes or glucose
of >11.0 mmol/l
0/50/0/50 Multicentre (19), Sweden 1990–1993
DIGAMI II AMI <24 h, type 2 diabetes or >11.0 mmol/l 42/36/0/22 Multicentre (44) International
(6, Europe)
1998–2003
HI-5 AMI <24 h with diabetes or >7.8 mmol/l 35/32/0/33 Multicentre (6) Australia 2001–2004
RCT randomised controlled trial, IDDM insulin dependent diabetes mellitus, AMI acute myocardial infarction, STEMI ST-elevation myocardial
infarction, GIK glucose–insulin–potassium infusion, ECG electrocardiogram
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The early randomised trials which were performed between
1994 and 2004 varied in size from 118 [32] to 20,195 [33]
and included patients in Europe [32, 34, 35] and other
continents [36, 37]. Reperfusion therapy was given as
thrombolysis or primary percutaneous coronary interven-
tion in less than 1% [31] to 100% of patients enrolled
[32]. Admission glucose values, when reported, varied
from 6.9 to 9 mmol/l and were similar across control and
GIK groups. All-cause mortality at 30–40 days was higher
in the GIK group in four of the six studies (reaching
statistical significance in Pol-GIK). In three studies that
reported longer follow-up (6–12 months) the mortality
difference in favour of the control group remained (also
reaching statistical significance in Pol-GIK). Two studies
showed a trend in cardiac [32] and all-cause (GIPS)
mortality in favour of GIK, though these did not reach
statistical significance. Because in GIPS a subgroup of
patients without heart failure had a lower 30-day mortality
in the GIK-treated group (1.2% vs. 4.2%, P=0.01), GIPS-
2 was set up excluding patients with symptoms of heart
failure, but this study did not show any beneficial effect of
GIK [34].
The differences in effect of GIK between the earlier and
more recent studies can be explained by improvements in
treatment (including reperfusion, antiplatelet and β-blocker
therapy), which is reflected in the lower mortality rates of
the studies performed after 1987. In the more recent studies
all 30–40 day mortality rates were below 16%, which is the
mortality rate of GIK-treated patients in the meta-analysis
of trials from 1965 to 1987.
A parallel could be drawn between GIK and the
administration of intravenous magnesium in AMI patients;
Table 2 Study outcomes and glycaemic parameters
Study Treatment Patients Glucose target
range (mmol/l)
Glucose level
(mmol/l±SD)
Mortality (%) Long-term mortality
Admission 16–
24 h
30–
40 days
HR(95% CI) P % Months P
Fath et al. [31] Control 972 21
GIK 956 16 0.76 (0.6–0.9) 0.004 –
Pol-GIK Control 460 – 7 6.2 4.8 6.5
GIK 494 <16.8 6.9 5.9 8.9 1.85 (1.1–3.1) 0.01 11.1 6 0.01
Krljanac
et al. [32]
Control 40 – 10.0b 4.0
GIK 78 – 3.0b 0.30 (0.0–1.4) 0.08 10.0 12 0.18
GIPS I Control 464 – 8.5 8.1 5.8 8.2
GIK 476 7.0–11.0 8.5 7.7 4.8 0.83 (0.5–1.4) 0.50 6.5 12 0.32
GIPS II Control 445 – 8.3±2.5 – 1.8 3.9
GIK 444 – 8.5±2.8 – 2.9 1.61 (0.7–3.8) 0.27 5.3 12 0.33
Create-ECLA Control 10,107 – 9.0 7.5 9.7 –
GIK 10,088 – 9.0 8.6 10 1.03 (0.9–1.1) 0.45 –
OASIS 6 Control 1374 – 6.7 10.4
GIK 1374 – 7.6 1.13 (0.9–1.5) 0.36 10.8 6 NS
DIGAMI I Control 314 15.7±4.2 11.7±4.1 15.6 26.1
Insulin 24 h+
3 months SC
306 7.0–10 15.4±4.1 9.6±3.3 12.4 0.79 (0.5–1.2) NS 18.6 12 0.027
DIGAMI II Standard practice 306 12.9±4.6 10.0±3.6 7.5 17
Insulin 24 h+
3 months SC
474 7.0–10.0+
fasting 5.0–7.0
12.8±4.5 9.1±3.0 7.5 1.00 (0.6–1.7) NS 15
Insulin 24 h 473 7.0–10.0 12.5±4.4 9.1±2.8 7.5 1.00 (0.6–1.6) NS 12 12 NS
HI-5 Control 114 11.1±3.5 9.0±2.8a 7.1c 7.9
Insulin/dextrose 126 4.0–10.0 10.8±4.1 8.3±2.2a 4.4c 0.62 (0.2–1.8) 0.42 6.1 6 0.62
SD standard deviation, HR hazard ratio, CI confidence interval, NS not statistically significant, GIK glucose–insulin–potassium, SC subcutaneous
insulin
aMean glucose over 24 h
b Cardiac mortality
cMortality at 3 months
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promising beneficial effects in smaller studies were not
confirmed in the large randomised MAGIC trial and the
concept was abandoned [38].
Conclusions
Insulin treatment in AMI patients has been investigated
extensively. The concept of systematic GIK in patients with
elevated or normal glucose levels was not supported by
recent trials in the reperfusion era and has been abandoned.
IGL targeted to achieve normoglycaemia can improve
survival and reduce incidence of adverse events. However,
achievement of glucose regulation is difficult and carries the
risk of hypoglycaemia. More research is needed to investigate
the role of computerised insulin protocols and continuous
glucose sensors to improve safety and efficacy of IGL.
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